We are live on ! Find out more
JSPR icon

Jasper Therapeutics

44 hedge funds and large institutions have $169M invested in Jasper Therapeutics in 2023 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 13 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

47,216% more capital inflows, than outflows

Capital inflows: $147M | Capital outflows: $310K

600% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 4

550% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 2

156% more call options, than puts

Call options by funds: $182K | Put options by funds: $71K

110% more funds holding

Funds holding: 21 → 44 (+23)

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

30.97% more ownership

Funds ownership: 54.62% → 85.59% (+31%)

Holders
44
Holders Change
+23
Holders Change %
+109.52%
% of All Funds
0.7%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
28
Increased
13
Reduced
2
Closed
4
Calls
$182​K
Puts
$71​K
Net Calls
+$111​K
Net Calls Change
+$111​K

JSPR Hedge Fund Activity: Q1 2023 in Review

44 of the 6,291 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q1 2023, worth a combined $169M — up 1,664% from $9.6M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new JSPR positions and 4 closed out — a net gain of 24 holders — while 13 added to existing stakes and 2 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $18.3M. The largest seller was Forefront Analytics, cutting an estimated $155K.

  • 44 institutional investors held Jasper Therapeutics (JSPR) as of Q1 2023, up from 21 in Q4 2022.
  • Funds reported $169M of Jasper Therapeutics stock for Q1 2023, up 1,664% quarter-over-quarter.
  • 28 funds opened new Jasper Therapeutics positions in Q1 2023 and 4 closed out, a net change of +24 holders.
  • The largest Jasper Therapeutics buyer in Q1 2023 was BVF Inc, an estimated $18.3M added.
  • The largest Jasper Therapeutics seller in Q1 2023 was Forefront Analytics, an estimated $155K sold.

Based on aggregated 13F filings for Q1 2023.